DelMar Pharmaceuticals Provides Update on VAL-083 Clinical Trial and Outlines Corporate Objectives for 2015 January 12, 2015 • 8:00 AM EST
DelMar Pharmaceuticals Commences Offer to Exchange Common Stock for Outstanding Warrants January 8, 2015 • 8:00 AM EST
DelMar Pharmaceuticals' Promising New Data Support the Potential of VAL-083 to Meet Significant Unmet Medical Needs in the Treatment of Glioblastoma Multiforme November 17, 2014 • 8:00 AM EST
DelMar Pharmaceuticals Presents Preclinical Data Supporting VAL-083 as a Potential New Treatment in Glioblastoma at the Society of Neuro-Oncology Annual Meeting November 14, 2014 • 11:45 AM EST
DelMar Pharmaceuticals Announces September 30, 2014 Results and Provides Corporate Update November 10, 2014 • 8:00 AM EST
DelMar Pharmaceuticals Invited to Present New Data on VAL-083 in the Treatment of Glioblastoma Multiforme at the Society for NeuroOncology Annual Meeting November 6, 2014 • 8:00 AM EST
VAL-083 Demonstrates Promise as a Potential Treatment for Non-small Cell Lung Cancer October 9, 2014 • 8:44 AM EDT
DelMar Pharmaceuticals Announces Presentations at Upcoming Scientific Meetings October 6, 2014 • 11:47 AM EDT